DALLAS--(BUSINESS WIRE)--Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376). The ongoing phase Ib trial’s first two patients have both achieved minimal residual disease-negative (MRD-) complete responses, according to Januario Castro, M.D., Associate Clinical Professor, Bone Marrow Transplant Division of the University of California, San Diego (UCSD).
